News
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback